Company Profile

Akouos Inc. precision genetic medicine company focused on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals. The Company is focused on developing precision therapies for forms of sensorineural hearing loss. The Company's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The Company is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.

Employees

103

Sector

Biotechnology & Medical Research

More about the company

24/01/24	Akouos, Inc. Announces Positive Initial Clinical Results from the Phase 1/2 AK-OTOF-101 Study	CI
02/12/22	Akouos, Inc. Announces Executive and Board Changes	CI
01/12/22	Lilly Wraps Up Acquisition of Akouos	MT
01/12/22	Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Composite Index	CI
01/12/22	Eli Lilly and Company completed the acquisition of Akouos, Inc. from a group of shareholders.	CI
30/11/22	Eli Lilly's Buyout Offer Accepted by 81% Akouos Shareholders at Closing	MT
30/11/22	Akouos, Inc.(NasdaqGS:AKUS) dropped from S&P TMI Index	CI
29/11/22	Akouos, Inc.(NasdaqGS:AKUS) dropped from NASDAQ Biotechnology Index	CI
14/11/22	Akouos Q3 Loss Narrows	MT
14/11/22	Akouos, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
19/10/22	Piper Sandler Downgrades Akouos to Neutral From Overweight, Adjusts Price Target to $13 From $18	MT
19/10/22	William Blair Downgrades Akouos to Market Perform From Outperform	MT
19/10/22	Health Care Up Amid Earnings, Deals -- Health Care Roundup	DJ

19/10/22	Piper Sandler Downgrades Akouos to Neutral From Overweight, Adjusts Price Target to $13 From $18	MT
19/10/22	William Blair Downgrades Akouos to Market Perform From Outperform	MT
19/10/22	HC Wainwright Downgrades Akouos to Neutral from Buy	MT
29/09/22	William Blair Starts Akouos at Outperform	MT
18/05/22	Piper Sandler Adjusts Akouos' Price Target to $18 From $40, Reiterates Overweight Rating	MT

02/12/22	AKOUOS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
30/11/22	Lilly and Akouos Announce Expiration of Akouos Tender Offer	PR
14/11/22	AKOUOS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
14/11/22	AKOUOS, INC. : Results of Operations and Financial Condition (form 8-K)	AQ
14/11/22	Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights	AQ

01/12/22	Eli Lilly : a finalisé l'acquisition d'Akouos
30/11/22	Eli Lilly : vers l'acquisition de 81.1% des actions d'Akouos
19/10/22	Wall Street sluit hoger
19/10/22	Wall Street houdt winst vast
19/10/22	MÄRKTE USA/Börsen setzen Erholung fort

Manager	Title	Age	Since
Emmanuel J. Simons CEO	Chief Executive Officer	43	01/01/2016
Jean Phillips CTO	Chief Tech/Sci/R&D Officer	-	-
Aaron Tward CTO	Chief Tech/Sci/R&D Officer	-	10/03/2022

AKOUOS Stock

Stocks

AKUS

US00973J1016

Biotechnology & Medical Research

Latest news : AKOUOS

Analysts' recommendations: AKOUOS

Press Releases: AKOUOS

News in other languages: AKOUOS

Quotes and Performance

Managers and Directors: AKOUOS

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/12/22	Sachiyo Minegishi	Issuer sale	Chief Financial Officer	150,000	0.4060%
01/12/22	Sona Saira Ramasastry	Issuer sale	Director	16,000	0.0433%
01/12/22	Ed Mathers Mathers	Issuer sale	Director	16,000	0.0433%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AKOUOS	+1.06%	+0.91%	-	-	491M
ARGENX SE	+0.46%	-0.85%	+67.99%	+123.00%	55.63B
WUXI APPTEC CO., LTD.	+0.82%	+15.05%	+79.52%	+88.67%	52.25B
BIONTECH SE	+0.78%	+1.55%	-13.98%	-14.40%	23.07B
INSMED INCORPORATED	+1.83%	+7.11%	+4.95%	+419.78%	22.41B
WUXI BIOLOGICS (CAYMAN) INC.	+6.78%	+14.77%	+37.54%	-1.86%	17.32B
GENMAB A/S	+1.23%	+3.65%	+30.49%	-32.31%	15.94B
EXELIXIS, INC.	+1.42%	+7.50%	+25.24%	+191.14%	13.77B
PHARMAESSENTIA CORPORATION	-3.35%	+8.96%	+134.32%	+282.61%	13.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+4.21%	+11.01%	+33.13%	-	12.43B
Average	+1.57%	+4.78%	+44.36%	+132.08%	25.14B
Weighted average by Cap.	+1.35%	+5.13%	+50.51%	+123.63%